Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

被引：0
|
作者：
T. Sakakida
T. Ishikawa
Y. Chihara
S. Harita
J. Uchino
Y. Tabuchi
S. Komori
J. Asai
T. Narukawa
A. Arai
H. Tsunezuka
T. Kosuga
H. Konishi
M. Moriguchi
H. Yasuda
F. Hongo
M. Inoue
S. Hirano
O. Ukimura
Y. Itoh
T. Taguchi
K. Takayama
机构：
[1] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology, Graduate School of Medical Science
[2] Kyoto Prefectural University of Medicine,Outpatient Oncology Unit, University Hospital
[3] Kyoto Prefectural University of Medicine,Department of Pulmonary Medicine, Graduate School of Medical Science
[4] Kyoto Prefectural University of Medicine,Department of Dermatology, Graduate School of Medical Science
[5] Kyoto Prefectural University of Medicine,Department of Urology, Graduate School of Medical Science
[6] Kyoto Prefectural University of Medicine,Department of Otolaryngology
[7] Kyoto Prefectural University of Medicine,Head and Neck Surgery, Graduate School of Medical Science
[8] Kyoto Prefectural University of Medicine,Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science
[9] Kyoto Prefectural University of Medicine,Division of Digestive Surgery, Department of Surgery, Graduate School of Medical Science
[10] Kyoto Prefectural University of Medicine,Division of Endocrine and Breast Surgery, Department of Surgery, Graduate School of Medical Science
来源：
Clinical and Translational Oncology | 2020年 / 22卷
关键词：
Immune-related adverse events; Programmed cell death 1 blockade; Immune checkpoint inhibitors; Antinuclear antibodies; Autoimmune diseases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 927
页数：8
相关论文
共 50 条
  • [41] Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
    Weijie Ma
    Barbara M. Gilligan
    Jianda Yuan
    Tianhong Li
    Journal of Hematology & Oncology, 9
  • [42] Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
    Guo, Xiaodi
    Li, Wendong
    Hu, Jiexuan
    Zhu, Emily C.
    Su, Qiang
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (10) : 1345 - 1354
  • [43] Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
    Ma, Weijie
    Gilligan, Barbara M.
    Yuan, Jianda
    Li, Tianhong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [44] Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis
    Liu, Xi
    Guo, Chang-Ying
    Tou, Fang-Fang
    Wen, Xiao-Ming
    Kuang, Yu-Kang
    Zhu, Qian
    Hu, Hao
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 116 - 127
  • [45] Possibility of PD-1/PD-L1 inhibitors for the treatment of patients with chronic hepatitis B infection
    Su, Menghan
    Ye, Ting
    Wu, Wei
    Shu, Zheyue
    Xia, Qi
    DIGESTIVE DISEASES, 2024, 42 (01) : 53 - 60
  • [46] Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer
    Gao, Ya
    Shi, Shuzhen
    Ma, Wenjuan
    Chen, Ji
    Cai, Yitong
    Ge, Long
    Li, Lun
    Wu, Jiarui
    Tian, Jinhui
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 72 : 374 - 384
  • [47] Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
    Kumar, Utpal
    Anthony, Michael Leonard
    Sahai, Rishabh
    Mittal, Ankur
    Durgapal, Prashant
    Kishore, Sanjeev
    JOURNAL OF LABORATORY PHYSICIANS, 2022, 14 (02) : 197 - 201
  • [48] Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
    Jahangir, Mohammadsaleh
    Yazdani, Omid
    Kahrizi, Mohammad Saeed
    Soltanzadeh, Sara
    Javididashtbayaz, Hamidreza
    Mivefroshan, Azam
    Ilkhani, Saba
    Esbati, Romina
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [49] DNA damage response and PD-1/PD-L1 pathway in ovarian cancer
    Zhang, Tianyu
    Zheng, Shuangshuang
    Liu, Yang
    Li, Xiao
    Wu, Jing
    Sun, Yue
    Liu, Guoyan
    DNA REPAIR, 2021, 102
  • [50] Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
    Ai, Leilei
    Chen, Jian
    Yan, Hao
    He, Qiaojun
    Luo, Peihua
    Xu, Zhifei
    Yang, Xiaochun
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 3625 - 3649
12345